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Abstract 
Background 
Pre-labor rupture of the membranes prior to but close to term is associated with an 
increased risk of neonatal infection, but labor induction is associated with risks of 
prematurity. The balance of risks is unclear. 
 
Aims  
To test the hypothesis that a policy of inducing labor reduces neonatal infection without 
increasing other morbidity.  
 
Methods 
A multicenter randomized controlled trial. Participants were women with ruptured 
membranes prior to the onset of labor between 34+0 and 36+6 weeks, and no clinical 
signs of infection. The experimental group had labor induced immediately. Participants 
in the control group awaited the spontaneous onset of labor.  The primary outcome was 
definite or probably neonatal infection. 
 
Main results. The induction policy did not reduce neonatal infection. 23/923 (2.5%) 
intervention and 29/912 (3.2%) expectant;  RR 0.8 (95% CI 0.5 – 1.3).  Rates of 
perinatal death (3 immediate v 3 expectant), ventilation more than 24 hours 56 (6.1%) 
v 37 (4.1%) or infection were combined into a predefined composite neonatal 
morbidity outcome 73 (7.9%) immediate v 61 (6.7%) expectant RR 1.2 (0.9-1.6). 
However babies born to the immediate delivery group had increased rates of 
respiratory distress (76 (8.3%) v 47 95.2%) RR 1.6 (1.1 – 2.30 and any mechanical 
ventilation 114 (12.4%) v 83 (9.1%), RR 1.4 (1.0-1.8) and spent more time in newborn 
intensive or special care median 4 v 2 days P = 0.001. 
 
Conclusion: In the absence of overt signs of infection or fetal compromise an expectant 
policy with regard to labor induction should be followed. 
 
Prelabor rupture of the membranes (rupture of the membranes prior to the onset of 
labor) occurs in 20% of all births and 40% of all preterm births. At term there is good 
evidence that immediate delivery is associated with a lower incidence of maternal 
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infection and increased maternal satisfaction compared with expectant management, 
with no attendant risks of perinatal morbidity or mortality.1  In contrast the optimal 
management of women with preterm prelabor rupture of membranes (PPROM) prior 
to 37 weeks, is not clear.2 
 
There is substantial practice variation internationally particularly in women who 
present near term, beyond 34 weeks gestation.3-5  Planned immediate delivery is both 
practiced4 and recommended based upon conclusions that  “compared with expectant 
management, induction of labor is associated with shorter latency to delivery and lower 
risk for maternal infection without excess risk for cesarean delivery”.6 This is despite 
recognition by professional bodies  such as the American and British Colleges of 
Obstetricians and Gynecologists that such recommendations are “based on limited and 
inconsistent scientific evidence.7,8 
 
Unlike PROM at term, pre-term PROM, therefore, continues to pose a clinical dilemma. 
The risks from delay  such as placental abruption, ascending infection, intrapartum fetal 
distress and cord prolapse9,10  need to be balanced against the risks of iatrogenic 
prematurity from immediate delivery. At extreme preterm gestations (less than 30 
weeks), in the absence of established infection or maternal or fetal compromise, there is 
unanimity  that expectant management is desirable5 because the risk of neonatal 
mortality, intraventricular hemorrhage, hyaline membrane disease and necrotizing 
enterocolitis. However, tThese risksare reduced as the gestational age extends towards 
term.11  Recommendations for immediate delivery  following preterm ruptured 
membranes close to term require grounding in good clinical evidence as even mild 
prematurity is associated with a significant health burden both in the short and long 
term.12  We undertook an international multicentre randomized controlled trial to 
establish the optimal management of birth following preterm premature rupture of the 
membranes close to term (PPROMT): comparing immediate delivery with expectant 
management, the PPROMT Trial (ISRCTN44485060) 
 
Methods 
Recruitment 
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Eligible women were aged over 16 with a singleton pregnancy and  clinically suspected 
ruptured membranes between 340 weeks and 366 weeks gestation. Women who 
presented with ruptured membranes earlier in pregnancy became eligible if they 
reached  34 weeks gestation. Exclusion criteria were established labor, 
chorioamnionitis, meconium staining, or any other contraindication to continuing the 
pregnancy. Group B streptococcus (GBS) vaginal colonization was not an exclusion 
criterion. The study took place in 65 centers in 11 countries (Australia, New Zealand, 
Argentina, South Africa, Brazil, UK, Norway, Egypt, Uruguay, Poland, Romania) between 
May 2004 and June 2013. All participating centers had the facilities for mothers and 
babies born at 34 weeks, including respiratory support. The study was approved by the 
institutional ethics review boards of each clinical site. All participants gave written 
informed consent before enrollment. 
 
Protocol13 
Eligible women were identified by a local research coordinator or clinical staff, provided 
the trial information sheet, and after written informed consent  entry details were 
recorded on a trial entry form and they were randomized via a central telephone service 
using a computer generated randomization schedule in a 1:1 ration in balanced blocks 
of variable size, stratified by center. An automated process collected basic patient 
identifying information and, after confirmation that entry into the study was sought, a 
study number and the treatment allocation was provided. 
 
Participants were randomly assigned to immediate delivery or expectant management. 
The former group had delivery scheduled as close to randomization as possible and 
preferably within 24 hours. The mode of birth was determined by usual obstetric 
indications. For women randomized to expectant management, birth occurred after 
spontaneous labor, at term or when the attending clinician felt that birth was mandated 
according according to the usual indications. For much of the recruitment period 
antibiotics were considered best practice in the presence of preterm prelabor ruptured 
membranes14 and these were prescribed according to local protocols. Placental 
histology was encouraged but not uniformly requested. 
 
Study outcomes 
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The primary outcome was the incidence of either definite or probable neonatal sepsis 
determined by a central adjudication committee masked to the treatment allocation.  
 
Definite systemic neonatal infection (definite sepsis) was defined a positive culture of 
a known pathogen from blood or cerebrospinal fluid (CSF), the baby treated with 
antibiotics for 5 or more days (or died before 5 days), and the presence of clinical signs 
of infection.  For organisms of low virulence and/or high likelihood of skin 
contamination of the blood culture, such as coagulase negative staphylococcus, both a 
positive blood culture and an abnormal full blood count or abnormal C-Reactive Protein 
(CRP) were required. An abnormal full blood count (FBC) included abnormal white cell 
count [WCC] <5 x 109 /L or >30 x 109 /L, platelet count <100,000, neutrophil count <1.5 
x 109 /L or raised immature to total neutrophil ratio (I:T ratio >0.2).15,16  A CRP 
>10mg/L was considered abnormal.17,18 
 
Clinical signs of infection included respiratory distress (requiring ventilation, 
continuous positive airway pressure or supplemental oxygen for more than one hour), 
apnea, lethargy, abnormal level of consciousness, circulatory compromise (including 
hypotension, poor perfusion, need for inotropic support or volume expansion) and/or 
temperature instability (temperature <36oC or ≥38 oC). 
 
Probable neonatal infection was defined as the presence of clinical signs where the 
baby was treated with antibiotics for 5 or more days together with one or more of: an 
abnormal FBC; abnormal CRP; positive GBS antigen on bladder tap urine, blood or CSF; 
elevated CSF white cell count 5 (CSF WCC>100 x106/L); growth of a known virulent 
pathogen (eg GBS, E.coli, Listeria) from surface swab; or a histologic diagnosis of 
pneumonia in an early neonatal death. 
 
Pre-specified secondary neonatal outcomes13,19  included composite neonatal morbidity 
(sepsis, mechanical ventilation >24 hours, stillbirth or neonatal death), respiratory 
distress, perinatal mortality, pneumonia, mechanical ventilation (intermittent positive 
pressure ventilation, continuous positive airway pressure or high frequency 
ventilation) for greater than 24 hours, duration of stay in a neonatal intensive or special 
care unit, duration of stay in hospital, birth weight, Apgar score ≤7 at 5 minutes, 
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antibiotics in the first 48 hours, lumbar puncture, circulatory compromise requiring 
arterial line, fluid bolus or inotropic support, and receiving breast milk at discharge 
(exclusive or mixed feeding). Neonatal outcomes were obtained from diagnoses 
reported by the attending clinician in the medical records, and collected for 28 days or 
until discharge . 
 
Secondary maternal outcomes included antepartum or intrapartum hemorrhage, 
antepartum or postpartum thrombosis, cord prolapse, postpartum treatment with 
antibiotics, intrapartum fever (pyrexia ≥38.5C), postpartum hemorrhage (>1000 ml), 
mode of delivery, onset of labor and duration of hospitalization (total days from 
randomization to delivery, and from delivery to discharge or transfer).  
Chorioamnionitis was a trial entry exclusion criteria but this outcome is reported 
among the women with expectant management.  Placental swabs and histology were 
also collected if available.  
As far as I can see you’ve not reported the following maternal secondary outcomes from 
trial registration.   
2.3. Post-partum fever 
2.8. Assisted vaginal delivery 
2.9. Maternal satisfaction 
2.10. Views of care 
time to fully establish breast feeding 
2.13. Maternal emotional wellbeing 
2.14. Anxiety and depression 
 
 
Other measures: 
Where time of day of randomization or PPROM were missing, the hours from PPROM to 
randomization was imputed as the difference in days, plus 9 hours ( the median for non-
missing participants). Only cultures from vaginal swabs taken between PPROM and 
randomization were assessed and findings of ‘normal vaginal flora’ and ‘lactobacilli’ 
were classified as negative. All other patient characteristics were reported by the 
participants at trial entry or collected from medical records. 
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Statistical Analysis 
A sample size of 1812 (906 patients per arm) was necessary to detect a reduction in 
neonatal sepsis of 5% in the expectantly managed arm compared with 2.5% in the 
immediate delivery arm with a two-sided 5% significance level and a power of 80%. 
One interim analysis was performed in February 2010 by the independent data 
monitoring committee, prior to submission for further funding,  who reviewed the 
findings (506 women had been recruited) and recommended that the study continue. A 
difference of at least three standard deviations in interim analysis of a major endpoint 
was needed to justify stopping the trial.  
 
All analyses were by intention-to-treat. No participants were excluded from the primary 
intention to treat analysis due to protocol violations. The primary outcome was 
calculated as event numbers and percentages, by treatment allocation. Effect measures 
(relative risk [RR]) were calculated with a 95% confidence interval (95% CI), using 
expectant management as the reference group. Comparison of mean birthweight was 
performed using a t-test. Comparisons of maternal and infant length of stay (days) were 
performed using non-parametric Wilcoxon Mann-Whitney tests. There was no 
imputation for missing outcome data. Participants with missing data were excluded 
from calculation of secondary outcomes, with the numbers missing reported by group.  
 
Predefined  criteria for whether adjusted analyses were required19  were a relative 
difference of >15% between arms in the median duration from PROM to randomization; 
and/or  a >3 day difference in median gestational age at randomization. If either had 
been  met, adjusted logistic regression would have been performed. No adjustment to 
the level of statistical significance was made for multiple comparisons.  
Pre-specified subgroup analyses for the primary outcome of neonatal sepsis included 
time from PPROM until randomization (<48 hours, ≥48 hours); gestational week of 
PPROM (<34 weeks, ≥34 weeks); vaginal swab culture result (GBS, other abnormal 
flora); and antibiotic administration at randomization. 
 
Results 
between May 2004 and June 2013 a total of 1839 women were recruited into the study. 
Figure 1 demonstrates the flow of participants through the study. Thirteen women in 
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the immediate delivery arm did not receive the allocated intervention compared with 
only one protocol violation in the expectant management arm.  The primary outcome 
was assessed for 1835 (99.8%) of those women randomized (immediate delivery 923; 
expectant management 912). 
 
The baseline characteristics of the two arms were similar (Table 1). The median 
gestational age at randomization in each arm was 247 days and the median time in 
hours from ruptured membranes to randomization was 30.4 hours in the immediate 
delivery arm and 26.4 hours (13.4% lower) in the expectantly managed arm so no 
adjusted analyses were performed.  Figure 2 shows the difference in time between 
randomization and delivery for the two arms of the trial.  
 
At the time of randomization, approximately 40% of women in each arm had received 
antenatal steroids and 86% received antibiotics (Table 1). Any antibiotics prior to 
delivery were prescribed for 852 (92.3%) women in the immediate delivery arm and 
844 (92.5%) in the expectant management arm. In the expectant management arm 688 
(73.2%) women were managed in hospital and the remainder were sent home between 
randomization and delivery.  
 
Women randomized to expectant management were more likely to deliver following the 
spontaneous onset of labor, have a cephalic presentation at birth and deliver at a later 
gestation than those allocated to immediate delivery (Table 2). Six women randomized 
to “immediate delivery” delivered after 36 weeks including 5 who were found not to 
have PROM after randomization and 1 who self-discharged from the enrolling hospital 
and birthed later. 
 
The primary outcome of definite or probable neonatal sepsis occurred in 23 (2.5%) of 
the 923 neonates whose mothers were assigned to immediate delivery and 29 (3.2%) of 
the 912 neonates whose mothers were assigned expectant management (RR 0.8; 95% 
CI, 0.5 to 1.3) (Table 3). There was no significant difference in the composite measure of 
mortality and neonatal morbidity including sepsis, ventilation >24 hours and perinatal 
death, occurring in 73 (7.9%) of those allocated immediate delivery and 61 (6.7%) of 
those managed expectantly. However, those babies born following immediate delivery 
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had significantly lower birthweights, increased risk of respiratory distress and 
mechanical ventilation, and spent more time in newborn intensive care or special care 
nursery (Table 4). 
 
There were six perinatal deaths, three in each arm of the trial. Among women 
randomized to immediate delivery the deaths were from: sudden infant death 
syndrome (SIDS) (4 weeks of age); congenital abnormality (3 weeks of age); and fetal 
death at 35 weeks gestation associated with acute suppurative chorioamnionitis based 
on the autopsy report..  Among women randomized to expectant management the 
deaths were from: SIDS (5 weeks of age); a congenital abnormality (12 weeks of age); 
and one of unknown cause (at 24 hours of age).  
 
Expectant management was associated with a greater likelihood of antepartum 
hemorrhage (2.9% vs 5%) and intrapartum fever (0.8% vs 2.1%) (Table 3). Cesarean 
delivery occurred in 239 (25.9%) women allocated to immediate delivery compared 
with 169 (18.5%) of those women allocated to expectant care (RR 1.4; 95% CI, 1.2 to 
1.7).  Fifty six (6.1%) women in the expectant management arm were delivered because 
of choriamnionitis subsequent to randomization. 
 
Neonatal sepsis was not significantly associated with immediate delivery or expectant 
management in any of the strata of the prespecified subgroup analyses (Table 4).  
Immediate delivery had no influence on sepsis regardless of the gestational age at 
PPROM, the duration of PPROM or the administration of antibiotics at the time of 
PPROM. Of women managed expectantly 191 (?%) women had an abnormal organism 
isolated from the swab including 78 with GBS. In those allocated to immediate delivery 
190 (?%)  women had a swab collected that isolated an abnormal organism, including 
83 with GBS.  For women allocated to immediate delivery neonatal sepsis occurred in 
2.1% of neonates born to women who had a positive culture on their vaginal swab 
compared with 4.7% in those born to mothers with a positive culture and managed 
expectantly (RR 0.4; 95% CI, 0.1 to 1.4).  
 
Discussion 
This trial demonstrates that for women with ruptured membranes between 340 and 366 
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weeks gestation carrying a single fetus and no contraindication for expectant 
management, immediate delivery increased neonatal complications with no clinically 
significant decrease in neonatal sepsis. Therefore in contrast to recent guideline 
recommendations,6,8 we advocate that expectant management is preferred to 
immediate delivery in women with ruptured membranes close to term. 
 
This is the largest study to compare these two forms of currently accepted management. 
Older studies that included women with PROM at preterm gestations were unable to 
demonstrate any reduction in neonatal sepsis or differences in neonatal morbidity2  and 
two underpowered studies with inclusion criteria similar to the PPROMT Trial 
published while the present studty was ongoing also reported that immediate delivery 
did not reduce neonatal sepsis. 20 21  They concluded that there was no increase in 
neonatal morbidity or cesarean delivery. The PPROMT Trial is the most adequately 
powered study to demonstrate that immediate delivery does not reduce neonatal sepsis 
but does increase the likelihood of several aspects of early neonatal morbidity including 
respiratory distress, mechanical ventilation and duration of stay in newborn intensive 
care. This has significant implications for practice and widespread adoption of 
expectant management following ruptured membranes close to term is likely to have 
significant resource and economic benefits. 
 
The adoption of the practice of immediate delivery, advocated in recent guidelines is 
predicated on the fact that disability free survival rates following birth are very high. 
However, there is increasing concern about the risks of adverse outcome for late 
preterm neonates, with studies identifying an increased risk of neonatal morbidity 22, 
rehospitalisation in early childhood 23 and academic difficulties in children at school age 
24. These risks are thought to be associated with both gestational age and biological 
factors associated with the preterm birth, including PPROM 25,  however, immediate 
delivery does not appear to improve outcomes in preterm neonates and may exacerbate 
the risks of prematurity because of birth in the absence of labor and earlier gestational 
age.  Although expectant management in a potentially hostile intrauterine environment 
should be avoided, in a mother who remains well, with no evidence of clinical 
chorioamnionitis, expectant management provides an opportunity for spontaneous 
labor to develop and for adaptive changes to occur in the neonate resulting in decreased 
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risk of neonatal respiratory illness 26.  For some neonates, expectant management may 
also result in delivery at a substantially older gestational age. These factors may in turn 
result in a decrease in neonatal morbidity, decreased separation of mother and baby, 
improved breast feeding rates and a reduction in risk of adverse childhood outcomes.  
 
 
In circumstances such as PPROM, where the risks and benefits of immediate delivery 
compared with expectant management have been unclear, policy makers have called on 
clinicians to develop evidence-based data to assess risk/benefit ratios for diagnosis 
specific indications for delivery at late-preterm gestations 22 
 
 The PPROMT trial is sufficiently large to provide evidence of the risks and benefits 
associated with immediate delivery following PPROM. Risks identified with immediate 
delivery include an increase in  respiratory distress requiring ventilator support for the 
baby, an increase in duration of admission to a neonatal intensive care or special care 
nursery and an increased likelihood of cesarean for the mother. On the other hand 
expectant management does not appear to significantly increase the likelihood of 
neonatal sepsis, but resulted in a lengthier hospital stay for the mother as most were 
managed as inpatients.  This is important information that care providers can discuss 
with women regarding best practice in this clinical situation. 
 
 
Although expectant management was provided according to each hospital’s current 
usual care, 75% of women were managed as inpatients and over 90% received 
antibiotics prior to delivery.  Our findings suggest that expectant management should 
include careful monitoring for/heightened surveillance of fever, symptoms of 
chorioamnionitis and antepartum hemorrhage.  
 
In addition to its size, the strengths of the PPROMT trial include the fact that it reflects 
contemporary maternity practice, was centrally randomized, had near complete follow 
up and was conducted across a range of international settings making the results widely 
generalizable. Many previous studies evaluating the management of ruptured 
membranes were small and performed prior to the widespread implementation of 
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maternal antibiotic administration to prolong latency and reduce short term morbidity, 
including neonatal infection.14,27-32  The PPROMT Trial results, together with the results 
of the recent PPROMEXIL studies,20,21 suggest there are benefits from expectant 
management without incurring significant risk of harms. It may be possible that there 
are groups of women who benefit from immediate delivery. Contrary to a recent 
report,33 our findings were that immediate delivery did not confer benefit on the 
women in whom Group B Streptococcus was isolated from the genital tract. There are 
opportunities to explore such risk factors further to identify specific indications for 
which immediate delivery is appropriate by performing an individual patient data 
meta-analysis of all those who participated in PPROMT and PPROMEXIL. 
 
Conclusion 
Contrary to the advice of many current guidelines, the PPROMT Trial found that 
expectant management does not increase the risk of neonatal sepsis but reduces 
neonatal morbidity in neonates of women who present with ruptured membranes close 
to term and that this should be advocated as best practice internationally.  
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Figure 1: Randomization and follow-up of study participants 
 
 
 
 
 
 
 
 
1839 women randomized 
Allocated to Expectant Management (n=915) 
1 woman did not receive allocated intervention 
3 women lost to follow-up 
912 analyzed 
 
923 analyzed 
1 woman lost to follow-up 
Allocated to Immediate Delivery (n=924) 
13 women did not receive allocated intervention 
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Figure 2: Time from randomization until birth, by treatment assignment 
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Table 1  Maternal and pregnancy factors at or before time of randomization, by 
treatment assignment 
 
 Immediate 
delivery 
N=923 
n (%) 
Expectant 
management 
N=912 
n (%) 
Rupture of membranes   
   <280 weeks   13 (   1.4)   14 (   1.5) 
   280 to 296 weeks   14 (   1.5)     9 (   1.0) 
   300 to 316 weeks   21 (   2.3)   34 (   3.7) 
   320 to 336 weeks 161 ( 17.4) 129 ( 14.1) 
   340 to 346 weeks 212 ( 23.0) 225 ( 24.7) 
   350 to 356 weeks 279 ( 30.2) 271 ( 29.7) 
   360 to 366 weeks 223 ( 24.2) 230 ( 25.2) 
Randomised   
   340 to 346 weeks 363 ( 39.3) 355 ( 38.9) 
   350 to 356 weeks 278 ( 30.1) 292 ( 32.0) 
   360 to 366 weeks 282 ( 30.6) 265 ( 29.1) 
PPROM ≥ 48 hours before randomization 328 ( 35.5) 302 ( 33.1) 
Maternal age (years) (mean, std.dev.) 27.9 ( 6.2) 28.0 ( 6.2) 
Previous pregnancies   
   0 426 ( 46.2) 430 ( 47.1) 
   1 232 ( 25.1) 241 ( 26.4) 
   ≥ 2 265 ( 28.7) 241 ( 26.4) 
Cephalic presentation 880 ( 95.3) 876 ( 96.1) 
Previous cesarean delivery   93 ( 10.1)   85 ( 9.3) 
Previous PPROM or preterm delivery 137 ( 14.8) 125 ( 13.7) 
Previous stillbirth or neonatal death   21 (   2.3)   24 (   2.6) 
Pregnancy hypertension (onset ≥ 20 weeks)   24 (   2.6)   33 (   3.6) 
Gestational diabetes   50 (   5.4)   48 (   5.3) 
Antenatal urinary tract infection   99 (   10.7)   87 (   9.5) 
Antibiotics given*   
   intravenous (+/- oral) 321 ( 34.8) 286 ( 31.4) 
   oral only 473 ( 51.2) 500 ( 54.8) 
Steroids given 383 ( 41.5) 354 ( 38.8) 
Positive culture from a vaginal swab†   
   any positive culture 190 ( 20.6) 191 ( 20.9) 
   Group B streptococcus positive   83 (   9.0)   78 (   8.6) 
 
 
*   antibiotics at randomization or in preceding 48 hours 
†  culture resulting from vaginal swab after PPROM and at or before randomization 
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Missing data (#immediate delivery, # expectant management): Previous CS (1,1); Previous PPROM (0,1); 
Previous stillbirth (0,1); Antibiotics (2,4); Positive culture (223,230)  
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Table 2  Labor characteristics, by treatment assignment 
 
Labor characteristic  Immediate 
delivery 
N=920 
n (%) 
Expectant 
management 
N=915 
n (%) 
P value 
Onset of labor    
   Spontaneous 180 ( 19.5) 549 ( 60.2) <0.0001* 
   Induced 647 ( 70.1) 310 ( 34.0)  
   Pre-labor cesarean   96 ( 10.4)   53 (   5.8)  
Cephalic presentation at birth     49 (   5.3)   33 (   3.6) <0.0001† 
Gestational age at birth 315 ( 34.1) 161 ( 17.7)  
   34 weeks 273 ( 29.6) 268 ( 29.4)  
   35 weeks 306 ( 33.2) 295 ( 32.3)  
   36 weeks   23 (  2.5) 174 ( 19.1)  
   37 weeks     1 (   0.1)     7 (   0.8)  
   38 weeks     1 (   0.1)     2 (   0.2)  
   39 weeks     1 (   0.1)     5 (   0.5)  
   40 weeks     3 (   0.3)     0 (   0.0)  
   41 weeks 180 ( 19.5) 549 ( 60.2) <0.0001* 
* P value for difference in mode of delivery across treatment groups 
† Wilcoxon P value for test of null hypothesis of no difference in distribution between treatment arms 
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Table 3   Infant and maternal outcomes by treatment assignment 
 
Infant outcome Immediate 
delivery 
n (%) 
Expectant 
management 
n (%) 
Relative risk 
RR (95% CI) 
Neonatal sepsis 23/ 923 ( 2.5) 29/ 912 ( 3.2) 0.8 ( 0.5, 1.3) 
Secondary infant outcomes    
Composite of neonatal morbidity (sepsis, 
ventilation ≥24 hours or death) 
73/ 923 ( 7.9) 61/ 911 ( 6.7) 1.2 ( 0.9, 1.6) 
Perinatal death 3/ 923 ( 0.3) 3/ 910 ( 0.3) 1.0 ( 0.2, 4.9) 
Respiratory distress syndrome 76/ 919 ( 8.3) 47/ 910 ( 5.2) 1.6 ( 1.1, 2.3) 
Pneumonia 3/ 919 ( 0.3) 4/ 910 ( 0.4) 0.7 ( 0.2, 3.3) 
Any mechanical ventilation (CPAP or 
ETT) 
114/ 923 (12.4) 83/ 912 ( 9.1) 1.4 ( 1.0, 1.8) 
  mechanical ventilation for ≥ 24 hours 56/ 923 ( 6.1) 37/ 912 ( 4.1) 1.5 ( 1.0, 2.2) 
Mean birthweight in grams (SD) 2574.7 ( 400.3) 2673.2 ( 405.5) <.0001 
SGA <10th percentile size 32/ 922 ( 3.5) 35/ 906 ( 3.9) 0.9 ( 0.6, 1.4) 
Apgar score <7 at 5 minutes 15/ 918 ( 1.6) 18/ 906 ( 2.0) 0.8 ( 0.4, 1.6) 
Antibiotics in first 48 hours 422/ 920 (45.9) 398/ 910 (43.7) 1.0 ( 0.9, 1.2) 
Lumbar puncture 33/ 921 ( 3.6) 38/ 911 ( 4.2) 0.9 ( 0.5, 1.4) 
Circulatory compromise 11/ 921 ( 1.2) 13/ 910 ( 1.4) 0.8 ( 0.4, 1.9) 
Infant days in hospital* 6.0 ( 3.0, 10.0) 4.0 ( 3.0, 8.0) <.0001 
Days in SCN/NICU†* 4.0 ( 0.0, 10.0) 2.0 ( 0.0, 7.0) <.0001 
Receiving breast milk at discharge 
 
695/ 883 (78.7) 712/ 877 (81.2) 1.0 ( 0.9, 1.0) 
Secondary maternal and pregnancy outcomes 
Antepartum hemorrhage 27/ 923 ( 2.9) 46/ 912 ( 5.0) 0.6 ( 0.4, 0.9) 
Cord prolapse 3/ 923 ( 0.3) 2/ 912 ( 0.2) 1.5 ( 0.2, 8.8) 
Intrapartum fever 7/ 923 ( 0.8) 18/ 912 ( 2.0) 0.4 ( 0.2, 0.9) 
Postpartum antibiotics 151/ 923 (16.4) 180/ 912 (19.7) 0.8 ( 0.7, 1.0) 
Postpartum hemorrhage (PPH) 29/ 803 ( 3.6) 27/ 782 ( 3.5) 1.0 ( 0.6, 1.8) 
Maternal duration of hospitalization* 5.0 ( 3.0, 7.0) 6.0 ( 4.0, 9.0) <.0001 
Cesarean delivery (CD) 239/ 923 (25.9) 169/ 912 (18.5) 1.4 ( 1.2, 1.7) 
    CD  following spontaneous labor  24/ 180 (13.3) 54/ 549 ( 9.8) 1.4 ( 0.9, 2.1) 
    CD following labor induction 119/ 647 (18.4) 62/ 310 (20.0) 0.9 ( 0.7, 1.2) 
    Pre-labor cesarean delivery 
 
Missing but pre-specified secondary 
outcomes 
 
2.3. Post-partum fever 
2.8. Assisted vaginal delivery 
2.9. Maternal satisfaction 
2.10. Views of care 
time to fully establish breast feeding 
2.13. Maternal emotional wellbeing 
96/ 923 (10.4) 53/ 912 ( 5.8) 1.8 ( 
1.3, 
2.5) 
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2.14. Anxiety and depression 
 
 
 
CPAP continuous positive pressure ventilation; ETT endotracheal tube; SD standard deviation; SGA small 
for gestational age; SCN special care nursery; NICU neonatal intensive care 
*  median and interquartile range reported for duration of admission, Wilcoxon P value for test of null 
hypothesis of no difference in distribution between treatment arms 
†  days in a Special Care Nursery and/or Neonatal Intensive Care Unit 
Missing data (#immediate delivery, # expectant management): composite (0,1); perinatal death (0,2); 
RDS (4,2); Pneumonia (4,2); birthweight (0,2); SGA (1,6), Apgar (5,6); antibiotics (3,2); lumbar puncture 
(2,1); Circulatory compromise (2,2) infant days in hospital (2,3); days in SCN/NICU (1,2); Breast milk at 
discharge (40,35); PPH (120,130); maternal duration of hospitalization (2,2)
22 
 
Table 4: Pre-specified subgroup analyses for neonatal sepsis by treatment 
assignment 
 
Infant outcome Immediate 
delivery 
Sepsis 
n/N (%) 
Expectant 
management 
Sepsis 
n/N (%) 
Neonatal 
sepsis 
RR (95% CI) 
Duration from PPROM to randomization     
  < 48 hours 19/ 595 ( 3.2) 18/ 610 ( 3.0) 1.1 ( 0.6, 2.0) 
  ≥ 48 hours 4/ 328 ( 1.2) 11/ 302 ( 3.6) 0.3 ( 0.1, 1.0) 
Gestation of PPROM    
  before 34 weeks 4/ 209 ( 1.9) 7/ 186 ( 3.8) 0.5 ( 0.2, 1.7) 
  ≥ 34 weeks 19/ 714 ( 2.7) 22/ 726 ( 3.0) 0.9 ( 0.5, 1.6) 
Vaginal culture after PPROM*    
  GBS  3/ 83 ( 3.6) 3/ 78 ( 3.8) 0.9 ( 0.2, 4.5) 
  other organism 1/ 107 ( 0.9) 6/ 113 ( 5.3) 0.2 ( 0.0, 1.4) 
  negative or no culture collected 19/ 733 ( 2.6) 20/ 721 ( 2.8) 0.9 ( 0.5, 1.7) 
Vaginal culture after PPROM*    
  Any culture positive  4/ 190 ( 2.1) 9/ 191 ( 4.7) 0.4 ( 0.1, 1.4) 
  Negative or no culture collected 19/ 733 ( 2.6) 20/ 721 ( 2.8) 0.9 ( 0.5, 1.7) 
Maternal antibiotics at randomization†    
  Yes  20/ 795 ( 2.5) 24/ 787 ( 3.0) 0.8 ( 0.5, 1.5) 
  No 3/ 127 ( 2.4) 5/ 122 ( 4.1) 0.6 ( 0.1, 2.4) 
*   culture from vaginal swab after PPROM and at or before randomization 
†  antibiotics at randomization or in preceding 48 hours 
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